Современный подход к антибактериальной терапии в практике хирурга
https://doi.org/10.20340/vmirvz.2021.2.CLIN.6
Аннотация
Ключевые слова
антибиотики,
резистентность,
бактериофаги,
профилактическая медицина,
антимикробные пептиды,
рана области оперативного вмешательства
УДК: 616-055.33
Об авторах
А. М. Морозов
Тверской государственный медицинский университет
Россия
Россия
Морозов Артем Михайлович кандидат медицинских наук, доцент кафедры общей хирургии
Тверь
SPIN-код 6815-9332
А. Н. Сергеев
Тверской государственный медицинский университет
Россия
Россия
Сергеев Алексей Николаевич доктор медицинских наук, доцент, заведующий кафедры общей хирургии
Тверь
SPIN-код 8817-0158
Э. М. Аскеров
Тверской государственный медицинский университет
Россия
Россия
Аскеров Эльшад Магомедович кандидат медицинских наук, доцент кафедры общей хирургии
Тверь
SPIN-код 5529-8581
С. В. Жуков
Тверской государственный медицинский университет
Россия
Россия
Жуков Сергей Владимирович доктор медицинских наук, профессор кафедры общественного здоровья и здравоохранения
Тверь
SPIN-код 7604-1244
Н. С. Новикова
Тверской государственный медицинский университет
Россия
Россия
Новикова Надежда Сергеевна студентка 5 курса педиатрического факультета
Тверь
М. А. Беляк
Тверской государственный медицинский университет
Россия
Россия
Беляк Мария Алексеевна студентка 3 курса лечебного факультета
Тверь
SPIN-код 5449-6580
Е. А. Соболь
Тверской государственный медицинский университет
Россия
Россия
Соболь Елизавета Алексеевна студентка 3 курса лечебного факультета
Тверь
SPIN-код: 3328-6389
Список литературы
1. Oppelaar M. C., Zijtveld C., Kuipers S. et al. Evaluation of Prolonged vs Short Courses of Antibiotic Prophylaxis Following Ear, Nose, Throat, and Oral and Maxillofacial SurgeryA Systematic Review and Meta-analysis». JAMA Otolaryngol Head Neck Surg. 2019;145(7):610-616. https://doi.org/10.1001/jamaoto.2019.0879
2. Luther A., Bisang C., Obrecht D. Advances in macrocyclic peptide-based antibiotics. Bioorg Med Chem. 2018;26:2850-2858. https://doi.org/10.1016/j.bmc.2017.08.006
3. Koehbach J., Craik D. The Vast structural diversity of antimicrobial peptides. Trends in Pharmacological Sciences. 2019;40(7):517-528. https://doi.org/10.1016/j.tips.2019.04.012
4. Musin H.G. Antimikrobnye peptidy – potencial'naya zamena tradicionnym antibiotikam. Infekciya i immun-itet. 2018;8(3):295-308. https://doi.org/10.15789/2220-7619-2018-3-295-308 (In Russ).
5. Upert G., Luther A., Obrecht D. et al. Emerging peptide antibiotics with therapeutic potential. Medicine in Drug Discovery. 2021;9. https://doi.org/10.1016/j.medidd.2020.100078
6. Yamamoto L.G. Treatment of Skin and Soft Tissue Infections. Pediatr Emerg Care. 2017;33(1):49-55. https://doi.org/10.1097/PEC.0000000000001001
7. Rodin A.V., Agafonov O.I. Tedizolid – novyj antibiotik dlya resheniya staryh problem: perspektivy prime-neniya dlya lecheniya oslozhnennyh infekcij kozhi i myagkih tkanej. Stacionarozameshchayushchie tekhnologii: Ambulatornaya hirurgiya. 2019;1-2. https://doi.org/10.21518/1995-1477-2019-1-2-80-86 (In Russ).
8. Zyryanov S.K., Sychev I.N., Gushchina YU.SH. Sovremennye problemy infekcij, vyzvannyh MRSA i puti ih resheniya. Antibiotiki i himioterapiya. 2017;7-8. https://doi.org/10.24411/0235-2990-2017-00011 (In Russ).
9. Dekhnich A.V., Hachatryan N.N. Novye i starye oksazolidinony. Tedizolid i linezolid – v chem otlichiya? КМАХ. 2017;19(2):121-129 eLIBRARY ID: 30064210.
10. Beloborodov V. B. Oslozhnennye infekcii kozhi i myagkih tkanej: sovremennye osobennosti anti-bakterial'noj terapii. Consilium Medicum. 2017;7-2. https://doi.org/10.26442/2075-1753_19.7.2.7-12 (In Russ).
11. Samarcev V.A., Gavrilov V.A., Parshakov A.A. et al. Profilaktika ranevyh infekcionnyh oslozhnenij posle gernioplastiki setchatymi protezami: eksperimental'no-klinicheskoe issledovanie. Klinicheskaya i eksper-imental'naya hirurgiya. 2020;8(1):12-21. https://doi.org/10.33029/2308-1198-2020-8-1-12-21 (In Russ).
12. Parshakov A.A., Gavrilov V.A., Samarcev V.A. Profilaktika oslozhnenij v hirurgii posleoperacion-nyh gryzh perednej bryushnoj stenki: sovremennoe sostoyanie problemy (obzor). Sovrem. tekhnol. med. 2018;10(2):1174-186. https://doi.org/10.17691/stm2018.10.2.21 (In Russ).
13. Natsional’nye klinicheskie rekomendatsii po gerniologii “Pakhovye i posleoperatsionnye gryzhi” / editors A.P. Ettingera, A.L. Shestakova, B.Sh. Gogiya. Moscow. 2018. (In Russ).
14. Yakovlev S.V., Zhuravleva M.V., Protsenko D.N. et al. Antibiotic stewardship program for inpatient care. Clinical guidelines for Moscow hospitals. Consilium Medicum. 2017; 9(7.1.Surgery): 15-51. (In Russ).
15. Parshikov V.V. Vospalitel'nye oslozhneniya proteziruyushchej plastiki bryushnoj stenki: diagnostika, lechenie i profilaktika (obzor). Sovrem. tekhnol. med. 2019;11(3):158-178. https://doi.org/10.17691/stm2019.11.3.19 (In Russ).
16. Gorshkova A.S., Dryukker V.V., Sykilinda N.N. Sovmestnoe vozdejstvie bakteriofagov i antibiotika na bioplyonku Pseudomonas aeruginosa. Antibiotiki i himioterapiya. 2020;3-4. https://doi.org/10.37489/0235-2990-2020-65-3-4-7-11 (In Russ).
17. Chan B.K., Turner P.E., Kim S. et al. Phage treatment of an aortic graft infected with Pseudomonas ae-ruginosa. Evolution, Medicine, and Public Health. 2018;1: 60-66. https://doi.org/10.1039/emph/eoy005
18. Aleksyuk M.S., Aleksyuk P.G., Bogoyavlenskij A.P. et al. Fagi Pseudomonas aeruginosa – kak al'terna-tivnyj podhod v antimikrobnoj terapii. Vestnik KazNMU. 2018;3:22-27. eLIBRARY ID: 36880158
19. Markelova N.N., Semenova E.F. Vozmozhnye puti preodoleniya antibiotikorezistentnosti nozokomial'nyh patogenov Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotropho-monas maltophilia. Antibiotiki i himioterapiya. 2018;11-12. https://doi.org/10.37489/0235-2990-2020-65-3-4-7-11 (In Russ).
20. Kazanova A.M., CHenkurov M.S., Kopajlo A.A. et al. Opredelenie effektivnosti antibakterial'noj terapii putyom provedeniya terapevticheskogo lekarstvennogo monitoringa. Antibiotiki i himioterapiya. 2020;3-4. https://doi.org/10.37489/0235-2990-2020-65-3-4-29-33 (In Russ).
21. CHernen'kaya T.V. Antibakterial'naya terapiya gnojno-septicheskih oslozhnenij v usloviyah ustojchivosti vozbuditelej k karbapenemam. NMP. 2017;6(1):34-40. https://doi.org/10.23934/2223-9022-2017-6-1-34-40 (In Russ).
22. Andryukov B.G., Zaporozhec T.S., Besednova N.N. Perspektivnye strategii poiska novyh sredstv bor'by s infekcionnymi zabolevaniyami. Antibiotiki i himioterapiya. 2018;63(1-2):44-55. https://doi.org/10.24411/0235-2990-2018-00015 (In Russ).
23. Chiu L., Bazin T., Truchetet M. et al. Protective microbiota: from localized to long-reaching co-immunity. Front Immunol. 2017;8:1678 https://doi.org/10.3389/fimmu.2017.01678.
24. Zaslavskaya M.I., Mahrova T.V., Aleksandrova N.A. et al. Perspektivy ispol'zovaniya bakteriocinov nor-mal'noj mikrobioty v antibakterial'noj terapii (obzor). Sovrem. tekhnol. med. 2019;11(3):136-145. https://doi.org/10.17691/stm2019.11.3.17 (In Russ).
25. Vakarina A.A., Kataeva L.V., Stepanova T.F. Vliyanie bakteriofagov na chuvstvitel'nost' uslovno pato-gennyh bakterij k antibakterial'nym preparatam. ZHurnal mikrobiologii, epidemiologii i immunobiologii. 2019;2:3-7. https://doi.org/10.36233/0372-9311-2019-2-3-7 (In Russ).
26. Efimenko T.A., Terekhova L.P., Efremenkova O.V. Sovremennoe sostoyanie problemy antibiotikore-zistentnosti patogennyh bakterij. Antibiotiki i himioterapiya. 2019;5-6:64-68. https://doi.org/10.24411/0235-2990-2019-10033 (In Russ).
27. YAkovlev S.V. Novaya koncepciya racional'nogo primeneniya antibiotikov v ambulatornoj praktike. Anti-biotiki i himioterapiya. 2019;3-4:47-57. https://doi.org/10.24411/0235-2990-2019-10017 (In Russ).
28. Strategiya preduprezhdeniya rasprostraneniya antimikrob-noy rezistentnosti v Rossiyskoy Federatsii na period do 2030 goda. Rasporyazhenie Pravitelstva Rossiyskoy Federatsii ot 25 sentyabrya 2017 goda, № 2045-r. (In Russ).
29. Altynpara A.I. Karbapenemazy – vyzov antibakterial'noj terapii. FORCIPE. 2019;2. ISSN 2658-4174 (In Russ).
30. Ferric C. Fang, Robert T. Schooley. Antimicrobial Resistance – The Glass Is Half Full. N Engl J Med. 2020; 382:1363-1365. https://doi.org/10.1056/NEJMe2002375
31. Nazarov P.A. Al'ternativy antibiotikam: liticheskie fermenty bakteriofagov i fagovaya terapiya. Vestnik RGMU. 2018;1:5-15. https://doi.org/10.24075/vrgmu.2018.002 (In Russ).
32. Il'ina T.S., Tolordava E.R., Romanova YU.M. Vzglyad na fagoterapiyu cherez 100 let posle otkrytiya bakteriofagov. Molekulyarnaya genetika, mikrobiologiya i virusologiya. 2019;3:103-112. https://doi.org/10.17116/molgen201937031103 (In Russ).
33. SHubnikova E.V., Merinova L.K., Senina T.V. et al. Bioplenki patogennyh burkkhol'derij i ih rol' v re-zistentnosti k antibiotikam. ZHurnal mikrobiologii, epidemiologii i immunobiologii. 2018;1:101-111. https://doi.org/10.36233/0372-9311-2018-1-101-111 (In Russ).
34. Atakishizade S.A.O. Osobennosti rezistentnosti k antibiotikam shtammov staphylococcus aureus, vydelennyh pri vnutribol'nichnyh infekciyah. Kazanskij med. zh. 2020;101(3):325-329. https://doi.org/10.17816/KMJ2020-325 (In Russ).
35. Egorov A.M., Ulyashova M.M., Rubcova M.YU. Bakterial'nye fermenty i rezistentnost' k antibiotikam. Acta Naturae. 2018;10;4(39):33-48. eLIBRARY ID: 36916320 (In Russ).
36. Kuz'menkov A.YU., Vinogradova A.G., Trushin I.V. et al. AMRcloud: novaya paradigma monitoringa anti-biotikorezistentnosti. KMAH. 2019;21(2)119-124. https://doi.org/10.36488/cmac.2019.2.119-124 (In Russ).
37. Zemlyanko O.M., Rogoza T.M., ZHuravleva G.A. Mekhanizmy mnozhestvennoj ustojchivosti bakterij k antibiotikam. Ekologicheskaya genetika. 2018;16(3):4-17. https://doi.org/10.17816/ecogen1634-17 (In Russ).
38. Nikulin A.A., Hachatryan N.N. Dalbavancin v terapii infekcij kozhi i myagkih tkanej. KMAH. 2018; 20. (4):320-340. https://doi.org/10.36488 / cmac.2018.4.320-340 (In Russ).
39. Olaniyi R., Pozzi C., Grimaldi L. et al. Staphylococcus aureus-Associated Skin and Soft Tissue Infec-tions: Anatomical Localization, Epidemiology, Therapy and Potential Prophylaxis. Curr Top Microbiol Im-munol. 2017;409:199-227. https://doi.org/10.1007/82_2016_32
40. Linder K.E., Nicolau D.P., Nailor M.D. Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. Hosp Pract (1995). 2017;45(1):9-15. https://doi.org/10.1080 / 21548331.2017.1279519
41. Romanov A.V., Dekhnich A.V., Sukhorukova M.V. et al. Antimicrobial resistance of nosocomial Staphy-lococcus aureus isolates in Russia: results of multicenter epidemiological study «MARATHON» 2013-2014. Klinicheskaja mimikrobiologija i antimikrobnaja himioterapija. 2017;19(1):57-62. (In Russ).
42. Abbas M., Paul M., Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacte-ria. Clin Microbiol Infect. 2017;23(10):697-703. https://doi.org/10.1016 / j.cmi.2017.06.010
43. Bal A.M., David M.Z., Garau J. et al. Future trends in the treatment of methicillin-resistant Staphylococ-cus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring patho-gen. Glob Antimicrob Resist. 2017;10:295-303. https://doi.org/10.1016 / j.jgar.2017.05.019
44. Van Harten R.M., Willems R.J.L., Martin N.I. et al. Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies? Trends Microbiol. 2017;25(6):467-479. https://doi.org/10.1016/ j.tim.2017.01.004
45. Pfaller M.A., Mendes R.E., Duncan L.R. et al. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. Antimicrob Chemother. 2018;73(10):2748-2756. https://doi.org/10,1093/jac/dky235
46. Guest J.F., Esteban J., Manganelli A.G. et al. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis. PLoS One. 2017;12(11):e0187792. https://doi.org/10.1371/journal.pone.0187792
47. Kussmann M., Obermueller M., Berndl F. et al. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Sci Rep. 2018;8(1):9661. https://doi.org/10.1038/s41598-018-28006-8
48. Diaz-Ruiz C., Alonso B., Cercenado E. et al. Can dalbavancin be used as a catheter lock solution? Med Microbiol. 2018;67:936-944. https://doi.org/10.1186/s12941-019-0329-6
49. Barber K.E., Tirmizi A., Finley R. et al. Dalbavancin Use for the Treatment of Methicillin-resistant Staphy-lococcus aureus Pneumonia. Pharmacol Pharmacother. 2017;8(2):77-79. https://doi.org/10.4103/jpp.JPP_2_17
50. Almangour T.A., Fletcher V., Alessa M. et al. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report. Case Rep. 2017;18:1315-1319. https://doi.org/10.12659/ajcr.905930
51. Galluzzo M., D'Adamio S., Bianchi L. et al. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. Expert Opin Drug Metab Toxicol. 2018;14(2):197-206. https://doi.org/10.1080/ 17425255.2018.1420162
52. Morozov A.M., Mohov E.M., Lyubskij I.V. et al. Vozmozhnosti razrabotki novogo biologicheski ak-tivnogo shovnogo materiala v hirurgii (obzor literatury). Vestnik eksperimental'noj i klinicheskoj hirurgii. 2019;3(44):193-198. https://doi.org/10.18499/2070-478X-2019-12-3-193-198 (In Russ).
53. Mohov E.M., Kadykov V.A., Sergeev A.N. et al. Ocenochnye shkaly boli i osobennosti ih primeneniya v medicine (obzor literatury). Verhnevolzhskij medicinskij zhurnal. 2019;18(2):34-37. eLIBRARY ID: 23903939 (In Russ).
54. Morozov A.M., ZHukova D.A. Rezul'taty lecheniya ostrogo appendicita. Materialy 61-j nauchnoj kon-ferencii studentov «Molodyozh', nauka, medicina», Tver', 23 aprelya 2015 g., RIC TGMA 2015 g. R. 138-141. eLIBRARY ID: 23903939 (In Russ).
55. Sergeev A.N., Morozov A.M., Askerov E.M. Metody lokal'noj antimikrobnoj profilaktiki infekcii oblasti hirurgicheskogo vmeshatel'stva. Kazanskij med. zh. 2020;101(2):243-248. https://doi.org/10.17816/KMJ2020-243 (In Russ).
Рецензия
Для цитирования:
Морозов А.М., Сергеев А.Н., Аскеров Э.М., Жуков С.В., Новикова Н.С., Беляк М.А., Соболь Е.А. Современный подход к антибактериальной терапии в практике хирурга. Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье. 2021;(2):79-86. https://doi.org/10.20340/vmirvz.2021.2.CLIN.6
For citation:
Morozov A.M., Sergeev A.N., Askerov E.M., Zhukov S.V., Novikova N.S., Belyak M.A., Sobol E.A. Modern approach to antibacterial therapy in the practice of a surgeon. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2021;(2):79-86. (In Russ.) https://doi.org/10.20340/vmirvz.2021.2.CLIN.6
Просмотров: 361
Послать статью по эл. почте 